All PlansAdministrativeMedium impact
Voluntary nationwide recall: Thyroid (Vitruvias – August 2026)
UPMC Health Plan·Endocrinology, Family Medicine, General Practice +2 more·Pharmacy
We identified it
Sep 12, 2026
Summary
Vitruvias Therapeutics Inc. has issued a voluntary nationwide recall of Thyroid Tablets, USP 30 mg, lot 504950, due to superpotency that may cause hyperthyroidism. This is a pharmacy safety alert requiring medical billing and clinical staff to identify affected patients, coordinate with providers and pharmacies, and ensure no disruption to patient care. No billing code changes are required, but practices must be aware for patient safety and potential follow-up claims related to adverse events or medication adjustments.
Action Required
Immediately: Billing and clinical staff must coordinate with providers to identify any patients currently prescribed Thyroid Tablets, USP 30 mg from lot 504950. Contact patients and their pharmacies to verify whether they received the recalled lot. Providers should review patient records for any claims or encounters related to hyperthyroidism symptoms (rapid heart rate, chest pain, weight loss, etc.) that may be linked to this medication. Do not deny or delay claims for patients requiring thyroid medication management or treatment of potential adverse effects. If patients require alternative thyroid medications or additional monitoring, ensure claims are processed without delay. Flag any adverse event reports for provider follow-up and potential future claims submission.